These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 35100094)

  • 1. Provider perceptions of medication for opioid used disorder (MOUD): A qualitative study in communities with high opioid overdose death rates.
    Paul N; Kennedy AJ; Taubenberger S; Chang JC; Hacker K
    Subst Abus; 2022; 43(1):742-748. PubMed ID: 35100094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. "Sick and tired of being sick and tired": Exploring initiation of medications for opioid use disorder among people experiencing homelessness.
    Swartz N; Adnan T; Peréa F; Baggett TP; Chatterjee A
    J Subst Abuse Treat; 2022 Jul; 138():108752. PubMed ID: 35277306
    [TBL] [Abstract][Full Text] [Related]  

  • 3. "They make it too hard and too many hoops to jump": system and organizational barriers to drug treatment during epidemic rates of opioid overdose.
    Dickson-Gomez J; Krechel S; Ohlrich J; Montaque HDG; Weeks M; Li J; Havens J; Spector A
    Harm Reduct J; 2024 Feb; 21(1):52. PubMed ID: 38413972
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medication for opioid use disorder treatment continuity post-release from jail: A qualitative study with community-based treatment providers.
    Stopka TJ; Rottapel RE; Ferguson WJ; Pivovarova E; Toro-Mejias LD; Friedmann PD; Evans EA
    Int J Drug Policy; 2022 Dec; 110():103803. PubMed ID: 35965159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Referral to and engagement in substance use disorder treatment within opioid intervention courts in New York: a qualitative study of implementation barriers and facilitators.
    O'Grady MA; Elkington KS; Robson G; Achebe IY; Williams AR; Cohall AT; Cohall R; Christofferson M; Garcia A; Ramsey KS; Lincourt P; Tross S
    Subst Abuse Treat Prev Policy; 2024 Jan; 19(1):12. PubMed ID: 38287329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Duration of medication treatment for opioid-use disorder and risk of overdose among Medicaid enrollees in 11 states: a retrospective cohort study.
    Burns M; Tang L; Chang CH; Kim JY; Ahrens K; Allen L; Cunningham P; Gordon AJ; Jarlenski MP; Lanier P; Mauk R; McDuffie MJ; Mohamoud S; Talbert J; Zivin K; Donohue J
    Addiction; 2022 Dec; 117(12):3079-3088. PubMed ID: 35652681
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Medications for opioid use disorder in state prisons: Perspectives of formerly incarcerated persons.
    Treitler PC; Enich M; Reeves D; Crystal S
    Subst Abus; 2022; 43(1):964-971. PubMed ID: 35420973
    [No Abstract]   [Full Text] [Related]  

  • 8. Prescribing and Acceptance of Medications for Opioid Use Disorder in VA Primary Care: Veteran and Provider Perspectives.
    Bergman AA; Oberman RS; Taylor SL; Kranke B; Chang ET
    J Gen Intern Med; 2024 Jul; 39(9):1690-1697. PubMed ID: 38587730
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Utilization of Medications for Opioid Use Disorder Across US States: Relationship to Treatment Availability and Overdose Mortality.
    Krawczyk N; Jent V; Hadland SE; Cerdá M
    J Addict Med; 2022 Jan-Feb 01; 16(1):114-117. PubMed ID: 35120067
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between jail-based methadone or buprenorphine treatment for opioid use disorder and overdose mortality after release from New York City jails 2011-17.
    Lim S; Cherian T; Katyal M; Goldfeld KS; McDonald R; Wiewel E; Khan M; Krawczyk N; Braunstein S; Murphy SM; Jalali A; Jeng PJ; MacDonald R; Lee JD
    Addiction; 2023 Mar; 118(3):459-467. PubMed ID: 36305669
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Jail-based reentry programming to support continued treatment with medications for opioid use disorder: Qualitative perspectives and experiences among jail staff in Massachusetts.
    Matsumoto A; Santelices C; Evans EA; Pivovarova E; Stopka TJ; Ferguson WJ; Friedmann PD
    Int J Drug Policy; 2022 Nov; 109():103823. PubMed ID: 35994938
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors associated with retention on medications for opioid use disorder among a cohort of adults seeking treatment in the community.
    Biondi BE; Vander Wyk B; Schlossberg EF; Shaw A; Springer SA
    Addict Sci Clin Pract; 2022 Mar; 17(1):15. PubMed ID: 35255967
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Payment-related barriers to medications for opioid use disorder: A critical review of the literature and real-world application.
    Bowser D; Bohler R; Davis MT; Hodgkin D; Horgan C
    J Subst Use Addict Treat; 2024 Oct; 165():209441. PubMed ID: 38906417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prior use of medications for opioid use disorder in ED patients with opioid overdose: prevalence, misuse and overdose severity.
    Shastry S; Nobel I; Allen LR; Richardson LD; Vidal K; Manini AF
    Am J Emerg Med; 2022 Jan; 51():114-118. PubMed ID: 34735968
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between treatment setting and outcomes among oregon medicaid patients with opioid use disorder: a retrospective cohort study.
    Hartung DM; Markwardt S; Johnston K; Geddes J; Baker R; Leichtling G; Hildebran C; Chan B; Cook RR; McCarty D; Ghitza U; Korthuis PT
    Addict Sci Clin Pract; 2022 Aug; 17(1):45. PubMed ID: 35986384
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treating opioid use disorder in veterans with co-occurring substance use: a qualitative study with buprenorphine providers in primary care, mental health, and pain settings.
    Frost MC; Soyer EM; Achtmeyer CE; Hawkins EJ; Glass JE; Hallgren KA; Williams EC
    Addict Sci Clin Pract; 2023 May; 18(1):26. PubMed ID: 37143162
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug use patterns and factors related to the use and discontinuation of medications for opioid use disorder in the age of fentanyl: findings from a mixed-methods study of people who use drugs.
    Hughto JMW; Tapper A; Rapisarda SS; Stopka TJ; Palacios WR; Case P; Silcox J; Moyo P; Green TC
    Subst Abuse Treat Prev Policy; 2023 May; 18(1):30. PubMed ID: 37217975
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Associations Between Inpatient Induction on Medications for Opioid Use Disorder and Postdischarge Medications for Opioid Use Disorder Adherence, Overdose, and Service Use.
    Noam KR; Schmutte TJ; Pirard S; Bourdon C; Langless D; Plant R
    J Addict Med; 2023 May-Jun 01; 17(3):e199-e201. PubMed ID: 37267183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Letting the sun shine on patient voices: Perspectives about medications for opioid use disorder in Florida.
    Sharp A; Carlson M; Howell V; Moore K; Schuman-Olivier Z
    J Subst Abuse Treat; 2021 Apr; 123():108247. PubMed ID: 33612190
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dialing for doctors: Secret shopper study of Arizona methadone and buprenorphine providers, 2022.
    Meyerson BE; Treiber D; Brady BR; Newgass K; Bondurant K; Bentele KG; Samorano S; Arredondo C; Stavros N
    J Subst Use Addict Treat; 2024 May; 160():209306. PubMed ID: 38296033
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.